Literature DB >> 23109605

Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment.

Daniel L Jacoby1, Eugene C DePasquale, William J McKenna.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23109605      PMCID： PMC3563885          DOI： 10.1503/cmaj.120138

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  95 in total

1.  Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1.

Authors:  J A Jarcho; W McKenna; J A Pare; S D Solomon; R F Holcombe; S Dickie; T Levi; H Donis-Keller; J G Seidman; C E Seidman
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

2.  Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide.

Authors:  C Pollick
Journal:  N Engl J Med       Date:  1982-10-14       Impact factor: 91.245

3.  Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration.

Authors:  C Pollick
Journal:  Am J Cardiol       Date:  1988-12-01       Impact factor: 2.778

4.  Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects.

Authors:  R O Bonow; V Dilsizian; D R Rosing; B J Maron; S L Bacharach; M V Green
Journal:  Circulation       Date:  1985-10       Impact factor: 29.690

5.  Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study.

Authors:  B J Maron; D D Savage; J K Wolfson; S E Epstein
Journal:  Am J Cardiol       Date:  1981-08       Impact factor: 2.778

6.  Electrocardiographic, echocardiographic and ventriculographic characterization of hypertrophic non-obstructive cardiomyopathy.

Authors:  H Yamaguchi; S Nishiyama; S Nakanishi; S Nishimura
Journal:  Eur Heart J       Date:  1983-11       Impact factor: 29.983

7.  Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy.

Authors:  L H Cohn; H Trehan; J J Collins
Journal:  Am J Cardiol       Date:  1992-09-01       Impact factor: 2.778

8.  The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes.

Authors:  A Pelliccia; B J Maron; A Spataro; M A Proschan; P Spirito
Journal:  N Engl J Med       Date:  1991-01-31       Impact factor: 91.245

9.  Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy.

Authors:  D R Rosing; U Idänpään-Heikkilä; B J Maron; R O Bonow; S E Epstein
Journal:  Am J Cardiol       Date:  1985-01-25       Impact factor: 2.778

10.  Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients.

Authors:  J S Child; J K Perloff; P M Bach; A D Wolfe; S Perlman; R A Kark
Journal:  J Am Coll Cardiol       Date:  1986-06       Impact factor: 24.094
View more
  9 in total

1.  Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.

Authors:  Sarah A Clay; Timothy L Domeier; Laurin M Hanft; Kerry S McDonald; Maike Krenz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

Review 2.  Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Karim Sallam; Yingxin Li; Philip T Sager; Steven R Houser; Joseph C Wu
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

3.  Letter to the Editor: Contemporary Screening and Treatment of Hypertrophic Cardiomyopathy.

Authors:  Fahed Darmoch; Mohamad Soud; Yasser Al-Khadra; Homam Moussa Pacha; M Chadi Alraies
Journal:  Ochsner J       Date:  2018

4.  Evaluation and Management of Concomitant Hypertrophic Obstructive Cardiomyopathy and Valvular Aortic Stenosis.

Authors:  John Shenouda; David Silber; Mythri Subramaniam; Basil Alkhatib; Richard K Schwartz; John A Goncalves; Srihari S Naidu
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-03

Review 5.  Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy.

Authors:  Catarina Roma-Rodrigues; Alexandra R Fernandes
Journal:  Appl Clin Genet       Date:  2014-10-03

Review 6.  Recent Advances in the Molecular Genetics of Familial Hypertrophic Cardiomyopathy in South Asian Descendants.

Authors:  Jessica Kraker; Shiv Kumar Viswanathan; Ralph Knöll; Sakthivel Sadayappan
Journal:  Front Physiol       Date:  2016-10-28       Impact factor: 4.566

7.  Echocardiography as a Screening Test for Myocardial Scarring in Children with Hypertrophic Cardiomyopathy.

Authors:  Gregory Compton; Lynne Nield; Andreea Dragulescu; Lee Benson; Lars Grosse-Wortmann
Journal:  Int J Pediatr       Date:  2016-11-15

Review 8.  Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy.

Authors:  Ishita Gupta; Nishant K Varshney; Sameena Khan
Journal:  Front Genet       Date:  2018-08-21       Impact factor: 4.599

9.  Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.

Authors:  Jamie R Bhagwan; Diogo Mosqueira; Karolina Chairez-Cantu; Ingra Mannhardt; Sara E Bodbin; Mine Bakar; James G W Smith; Chris Denning
Journal:  J Mol Cell Cardiol       Date:  2020-06-10       Impact factor: 5.000
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.